首页|期刊导航|时珍国医国药|痛风清消方通过OPG/RANKL/NF-κB信号通路调控湿热证痛风性关节炎大鼠骨代谢的机制研究

痛风清消方通过OPG/RANKL/NF-κB信号通路调控湿热证痛风性关节炎大鼠骨代谢的机制研究OA

Mechanism of Tongfeng Qingxiao Formula(痛风清消方)in regulating bone metabolism via the OPG/RANKL/NF-κB signaling pathway in rats with damp-heat gouty arthritis

中文摘要英文摘要

目的 探讨痛风清消方介导OPG/RANKL/NF-κB信号通路调控湿热证痛风性关节炎(GA)大鼠骨代谢的作用机制.方法 将60只SPF级雄性SD大鼠随机分为正常组、模型组、双氯芬酸钠组及痛风清消方高、中、低剂量组,每组10只.除正常组外,其余组别复制湿热证GA模型,造模期间分别给予相应药物干预.测量各组大鼠的踝关节肿胀度与步态评分,采用HE、番红-固绿及TRAP染色观察踝关节组织病理变化与破骨细胞数量,ELISA检测血清中炎症相关标志物IL-1β、IL-10、NF-κB和骨代谢相关标志物OPG、RANKL、CTX-I的表达水平,WB检测踝关节软骨组织OPG、RANK、RANKL蛋白表达水平,IHC法检测踝关节滑膜组织NF-κB p65蛋白表达水平.结果 与正常组比较,模型组大鼠踝关节肿胀度和步态评分显著升高(P<0.01),滑膜炎症细胞浸润、软骨结构破坏及破骨细胞数量显著增加(P<0.01),血清IL-1β、NF-κB、RANKL、CTX-I水平显著上升(P<0.01),IL-10、OPG水平显著下降(P<0.01),软骨组织RANK、RANKL和滑膜组织NF-κB p65蛋白表达水平显著升高(P<0.01),软骨组织OPG表达水平降低(P<0.01).与模型组比较,痛风清消方高、中剂量组能明显改善踝关节肿胀度和步态评分(P<0.05,P<0.01),抑制滑膜炎症和软骨破坏,降低破骨细胞数量(P<0.01),下调血清IL-1β、NF-κB、RANKL和CTX-I水平(P<0.05,P<0.01),上调IL-10和OPG水平(P<0.01),并显著回调软骨组织中OPG/RANKL/RANK蛋白表达水平及滑膜NF-κB p65蛋白表达水平(P<0.01),其效果与双氯芬酸钠组相当.结论 痛风清消方可能通过调控OPG/RANKL/NF-κB信号通路,抑制炎症反应、减少OC形成分化和调节骨代谢平衡,从而改善湿热证GA大鼠关节炎症与骨破坏.

Objective To investigate the mechanism by which Tongfeng Qingxiao Formula(痛风清消方,TFQXF)regulates bone metabolism via the OPG/RANKL/NF-κB signaling pathway in rats with damp-heat gouty arthritis(GA).Methods Sixty SPF-grade male SD rats were randomly divided into six groups(n=10 per group):normal control group,model group,diclofenac sodium group,and low/medium/high-dose TFQXF groups.Except for the normal control group,all other groups were subjected to the induction of a damp-heat syndrome GA model,with corresponding drug interventions administered during the modeling period.Ankle joint swelling and gait scores were assessed in each group.HE,Safranin O-Fast Green(SO-FG),and tartrate-resistant acid phosphatase(TRAP)staining were performed to observe pathological changes in ankle joint tissues and quantify osteoclasts(OCs).Serum levels of inflammation-related markers(IL-1β,IL-10,NF-κB)and bone metabolism-related markers(OPG,RANKL,CTX-I)were measured by enzyme-linked immunosorbent assay(ELISA).The protein expression levels of OPG,RANK,and RANKL in ankle cartilage tissue were detected by Western blot(WB),while NF-κB p65 expression in synovial tissue was examined using immunohistochemistry(IHC).Results Compared with the normal group,rats in the model group exhibited significantly increased ankle joint swelling and gait scores(P<0.01),along with marked synovial inflammatory cell infiltration,cartilage structural damage,and a significant elevation in OC numbers(all P<0.01).Serum levels of IL-1β,NF-κB,RANKL,and CTX-I were significantly elevated(P<0.01),whereas IL-10 and OPG levels were markedly decreased(P<0.01).In addition,protein expression of RANK and RANKL in cartilage tissue and NF-κB p65 in synovial tissue were significantly upregulated(P<0.01),while OPG expression in cartilage tissue was reduced(P<0.01).Compared with the model group,high/medium-dose TFQXF significantly ameliorated ankle swelling and gait scores(P<0.05,P<0.01),attenuated synovial inflammation and cartilage destruction,and reduced OC numbers(P<0.01).Moreover,it downregulated serum IL-1β,NF-κB,RANKL,and CTX-I levels(P<0.05,P<0.01),upregulated IL-10 and OPG levels(P<0.01),and signifi-cantly restored the protein expression of OPG,RANKL,and RANK in cartilage tissue as well as NF-κB p65 in synovial tissue(P<0.01).The effects were comparable to those in the diclofenac sodium group.Conclusion TFQXF may mitigate joint inflammation and bone destruction in rats with damp-heat GA by regulating the OPG/RANKL/NF-κB signaling pathway,thereby inhibiting inflammatory responses,mitigating OC formation and differentiation,and modulating bone metabolic balance.

袁启鹏;黄鑫;胡烈奎;孙伟康;邵子晨;马玮玮;吴东雨;陈扬;李华南

江西中医药大学,江西 南昌 330004江西中医药大学,江西 南昌 330004江西中医药大学,江西 南昌 330004江西中医药大学,江西 南昌 330004江西中医药大学,江西 南昌 330004江西中医药大学,江西 南昌 330004江西中医药大学,江西 南昌 330004江西中医药大学,江西 南昌 330004江西中医药大学附属医院,江西 南昌 330006

医药卫生

痛风性关节炎湿热证痛风清消方OPG/RANKL/NF-κB信号通路骨代谢

Gouty arthritisDamp-heat syndromeTongfeng Qingxiao Formula(痛风清消方)OPG/RANKL/NF-κB signal-ing pathwayBone metabolism

《时珍国医国药》 2026 (16)

3017-3024,8

国家自然科学基金(82060871,82560945)江西省科技厅领军人才项目(20243BCE51009)江西省自然科学基金重点项目(20232ACB206051)痹证重点研究室项目[赣中医药科教字(2022)8号]江西省卫生健康委科技计划项目(202510058)江西省中医优势病种(痛风)诊疗技术标准化项目(2024A012)

10.70976/j.1008-0805.SZGYGY-2026-1603

评论